Nothing Special   »   [go: up one dir, main page]

Terenius et al., 1972 - Google Patents

Aspects on the mode of action of antiestrogens and antiprogestogens

Terenius et al., 1972

Document ID
7751244358199093454
Author
Terenius L
Ljungkvist I
Publication year
Publication venue
Gynecologic and Obstetric Investigation

External Links

Snippet

Most so-called antiestrogens are 'estrogenic'in the mouse uterine growth test and in the Allen-Doisy test (in mice or rats). With regard to their uterotrophic effects, they were classified as giving normal (cis-and trans-clomiphene, ICI-46,474 and U-11,555 A); impeded (estriol …
Continue reading at karger.com (other versions)

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids
    • A61K31/565Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids
    • A61K31/565Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane, progesterone
    • A61K31/573Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane, progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids
    • A61K31/575Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids
    • A61K31/58Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138Aryloxyalkylamines, e.g. propanolol, tamoxifen, phenoxybenzamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/13Amines
    • A61K31/135Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137Arylalkylamines, e.g. amphetamine, epihephrine, salbutamol, ephedrine or methadone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/04Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08Peptides having 5 to 11 amino acids
    • A61K38/09Luteinising hormone-releasing hormone [LHRH], i.e. Gonadotropin-releasing hormone [GnRH]; Related peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/095Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A61K31/10Sulfides; Sulfoxides; Sulfones

Similar Documents

Publication Publication Date Title
Santen et al. Endocrine treatment of breast cancer in women
Mauvais-Jarvis et al. Antiestrogen action of progesterone in breast tissue
Taraborrelli Physiology, production and action of progesterone
Santen et al. Use of aromatase inhibitors in breast carcinoma.
DE69022722T2 (en) COMBINATION THERAPY FOR TREATING ESTROGEN SENSITIVE DISEASES.
Sitruk-Ware New progestogens: a review of their effects in perimenopausal and postmenopausal women
Terenius et al. Aspects on the mode of action of antiestrogens and antiprogestogens
Der Schoot et al. Effects of the progesterone antagonist RU486 on ovarian activity in the rat
Robbins et al. Mifepristone: clinical pharmacology
Tsai et al. Antagonism of development and growth of 7, 12-dimethylbenz (a) anthracene-induced rat mammary tumors by the antiestrogen U 23,469 and effects on estrogen and progesterone receptors
Huggins et al. The depression of growth of the uterus, adrenals, and ovaries by fluorinated steroids in the pregnane series
Clark et al. The agonistic and antagonistic actions of estriol
Schumacher et al. Neurosteroids: synthesis and functions in the central and peripheral nervous systems
Perusquía Nongenomic action of steroids in myometrial contractility
Aumüller et al. Phenotypic modulation of the canine prostate after long‐term treatment with androgens and estrogens
CALLANTINE Nonsteroidal estrogen antagonists
Burghardt et al. Gap junction modulation in rat uterus. III. Structure-activity relationships of estrogen receptor-binding ligands on myometrial and serosal cells
Mauvais-Jarvis et al. Antiestrogen action of progesterone in breast tissue
Götze et al. Anti-oestrogenic effects of tamoxifen on mammary gland and hypophysis in female rats
Schatz et al. In Vitro Inhibition with Antiestrogens of Estradiol Effects on Prostaglandin F2 α Production by Human Endometrium and Endometrial Epithelial Cells
Baulieu Aspects of steroid hormone-target cell interactions
Burghardt et al. Gap junction modulation in rat uterus. II. Effects of antiestrogens on myometrial and serosal cells
Sengupta et al. Effect of an estrogen antagonist on development of blastocysts and implantation in the hamster
Spicer et al. Effects of 2-hydroxyestradiol on the number of granulosa cell β-adrenergic receptors
JP2004511523A (en) Use of antiprogestin to induce apoptosis in cells